1Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea
2Samsung Genome Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
3Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
4Cancer of Companion Diagnostics, Innovative Cancer Medicine Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
5Life Science Solutions Group, Thermo Fisher Scientific Corporation, Seoul, Korea
6Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Copyright © 2016 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Variable | Total (n=174), n (%) | 5Y DRFS (%) | p-value |
---|---|---|---|
Age (yr) | |||
Median | 46.0±10.1 | - | |
Range | 23.5-73.1 | - | 0.469 |
< 40 | 46 (26.4) | 80.1 | |
≥ 40 | 128 (73.6) | 86.6 | |
Histology | |||
IDC | 154 (88.5) | 85.6 | 0.288 |
Other | 20 (11.5) | 80.0 | |
Stage | |||
I | 44 (25.3) | 88.4 | < 0.001 |
IIA | 87 (50.0) | 91.9 | |
IIB | 25 (14.4) | 75.8 | |
IIIA | 12 (6.9) | 64.8 | |
IIIB | 0 | NA | |
IIIC | 6 (3.4) | 33.3 | |
Nuclear grade | |||
1 | 2 (1.1) | 50.0 | 0.144 |
2 | 41 (23.6) | 82.7 | |
3 | 125 (71.8) | 87.1 | |
Unknown | 6 (3.4) | 66.7 | |
Histologic grade | |||
1 | 3 (1.7) | 100.0 | 0.606 |
2 | 39 (22.4) | 84.5 | |
3 | 122 (70.1) | 85.9 | |
Unknown | 10 (5.7) | 70.0 | |
p53 IHC | |||
Positive | 103 (59.0) | 85.4 | 0.151 |
Negative | 69 (40.0) | 81.2 | |
Unknown | 2 (1.1) | 50.0 | |
TP53 mutation | |||
Wild type | 97 (55.7) | 82.5 | 0.625 |
Missense | 49 (28.2) | 81.6 | |
Nonsense/Frameshift/Splicing | 28 (16.1) | 89.3 | |
TP53 mRNA expression | |||
Median | 228.52±147.81 | - | 0.593 |
Range | 32.40-736.09 | - | |
Low | 87 (50.0) | 81.6 | |
High | 87 (50.0) | 85.1 | |
Adjuvant CTx | |||
CMF | 76 (43.7) | 89.4 | 0.001 |
Anthracycline | 63 (36.2) | 90.3 | |
Anthracycline+taxane | 35 (20.1) | 65.5 | |
Adjuvant RTx | |||
Yes | 110 (63.2) | 82.5 | 0.109 |
No | 64 (36.8) | 89.0 |
Variable | Wild type (n=97) | Missense (n=49) | Deleterious (n=28) | p-value |
---|---|---|---|---|
p53 IHC | ||||
Positive | 52 (53.6) | 44 (89.8) | 7 (25.0) | < 0.001 |
Negative | 44 (45.4) | 4 (8.2) | 21 (75.0) | |
Unknown | 1 (1.0) | 1 (2.0) | 0 | |
TP53 expression | ||||
Median | 207.36±132.73 | 339.61±143.21 | 99.53±99.57 | < 0.001 |
Range | 32.40-634.93 | 50.02-736.09 | 43.81-391.99 | |
Low | 55 (56.7) | 8 (16.3) | 24 (85.7) | |
High | 42 (43.3) | 41 (83.7) | 4 (14.3) |
Variable | No. (%) (n=174) | 5Y DRFS (%) |
---|---|---|
TP53 wild type | ||
Low expression | 55 (31.6) | 81.8 |
High expression | 42 (24.1) | 83.3 |
TP53 missense mutation | ||
Low expression | 8 (4.6) | 50.0 |
High expression | 41 (23.6) | 87.8 |
TP53 nonsense/Frameshift/Splicing | ||
Low expression | 24 (13.8) | 91.7 |
High expression | 4 (2.3) | 75.0 |
Variable | Wild type (n=97) | Missense (n=49) | Deleterious (n=28) | p-value |
---|---|---|---|---|
Age (yr) | ||||
Median | 45.35±23.48 | 44.63±27.29 | 48.68±32.60 | 0.428 |
Range | 23.48-69.98 | 27.29-67.72 | 23.48-73.12 | |
< 40 | 25 (26.3) | 16 (31.4) | 5 (17.9) | |
≥ 40 | 70 (73.7) | 35 (68.6) | 23 (82.1) | |
Histology | ||||
IDC | 80 (84.2) | 47 (92.2) | 27 (96.4) | 0.128 |
Other | 15 (15.8) | 4 (7.8) | 1 (3.6) | |
Stage | ||||
I | 23 (24.2) | 15 (29.4) | 6 (21.4) | 0.441 |
IIA | 48 (50.5) | 20 (39.2) | 19 (67.9) | |
IIB | 13 (13.7) | 10 (19.6) | 2 (7.1) | |
IIIA | 8 (8.4) | 4 (7.8) | 0 | |
IIIB | 0 | 0 | 0 | |
IIIC | 3 (3.1) | 2 (3.9) | 1 (3.6) | |
Nuclear grade | ||||
1 | 1 (1.1) | 0 | 1 (3.6) | 0.669 |
2 | 24 (25.3) | 12 (23.5) | 5 (17.9) | |
3 | 67 (70.5) | 38 (74.5) | 20 (71.4) | |
Unknown | 3 (3.2) | 1 (2.0) | 2 (7.1) | |
Histologic grade | ||||
1 | 2 (2.1) | 1 (2.0) | 0 | 0.517 |
2 | 24 (25.3) | 9 (17.6) | 6 (21.4) | |
3 | 61 (64.2) | 40 (78.4) | 21 (75.0) | |
Unknown | 8 (8.4) | 1 (2.0) | 1 (3.6) | |
Adjuvant CTx | ||||
CMF | 39 (41.1) | 23 (45.1) | 12 (42.9) | 0.615 |
Anthracycline | 38 (40.0) | 15 (29.4) | 12 (42.9) | |
Anthracycline+taxane | 18 (18.9) | 13 (25.5) | 4 (14.3) | |
Adjuvant RTx | ||||
Yes | 57 (60.0) | 35 (68.6) | 18 (64.3) | 0.583 |
No | 38 (40.0) | 16 (31.4) | 10 (35.7) |
Variable | Low expression (n=87) | High expression (n=87) | p-value |
---|---|---|---|
Age (yr) | |||
Median | 48.14±10.26 | 45.65±9.94 | 0.105 |
Range | 23.48-69.98 | 27.29-67.72 | |
< 40 | 20 (23.0) | 26 (29.9) | |
≥ 40 | 67 (77.0) | 61 (70.1) | |
Histology | |||
IDC | 78 (89.7) | 76 (87.4) | 0.635 |
Other | 9 (10.3) | 11 (12.6) | |
Stage | |||
I | 23 (26.4) | 21 (24.1) | 0.126 |
IIA | 45 (51.7) | 42 (48.3) | |
IIB | 15 (17.2) | 10 (11.5) | |
IIIA | 2 (2.3) | 10 (11.5) | |
IIIB | 0 | 0 | |
IIIC | 2 (2.3) | 4 (4.6) | |
Nuclear grade | |||
1 | 1 (1.1) | 1 (1.1) | 0.847 |
2 | 18 (20.7) | 12 (26.4) | |
3 | 65 (74.7) | 38 (69.0) | |
Unknown | 3 (3.4) | 1 (3.4) | |
Histologic grade | |||
1 | 1 (1.1) | 2 (2.3) | 0.554 |
2 | 20 (23.0) | 19 (21.8) | |
3 | 63 (72.4) | 40 (67.8) | |
Unknown | 3 (3.4) | 1 (8.0) | |
Adjuvant CTx | |||
CMF | 33 (37.9) | 41 (47.1) | 0.417 |
Anthracycline | 35 (40.2) | 30 (34.5) | |
Anthracycline+taxane | 19 (21.8) | 16 (18.4) | |
Adjuvant RTx | |||
Yes | 54 (62.1) | 56 (64.4) | 0.753 |
No | 33 (37.9) | 31 (35.6) |
5Y DRFS, 5-year distant recurrence-free survival; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; CTx, chemotherapy; CMF, cyclophosphamide+methotrexate+5-fluorouracil; RTx, radiotherapy.
Values are presented as number (%) unless otherwise indicated. IHC, immunohistochemistry.
p=0.057. 5Y DRFS, 5-year distant recurrence-free survival.
Values are presented as number (%) unless otherwise indicated. IDC, invasive ductal carcinoma; CTx, chemotherapy; CMF, cyclophosphamide+methotrexate+5-fluorouracil; RTx, radiotherapy.
Values are presented as number (%) unless otherwise indicated. IDC, invasive ductal carcinoma; CTx, chemotherapy; CMF, cyclophosphamide+methotrexate+5-fluorouracil; RTx, radiotherapy.